Stryker (SYK) Stock Price

Stryker Price

🇺🇸NYSE·CLOSED
332.71USD
Market closed
Today +/-
Today %

Stryker (SYK) Stock | ISIN US8636671013 | WKN 864952. The current Stryker stock price is 332.71 USD (2026). Revenue is 27.59 B USD. Net income is 5.84 B USD. The P/E ratio is 22. Market capitalization is 128.59 B USD. Stryker operates in the Health sector.

Over the last 19 years Stryker grew revenue by 8.7% annually, reaching 25.12 B USD. Earnings per share have grown at 8.2% per year over the last 19 years. For Stryker, the net margin of 12.9% is up versus 11.7% a few years ago. At today's price the dividend yield works out to roughly 1.02%. The payout ratio is around 48% of earnings. The dividend has grown at 15.5% per year over the past 19 years.

Stryker stock price

Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Stryker over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Stryker stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Stryker's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Stryker Stock Price History
DateStryker Price
Access this data via the Eulerpool API

Stryker Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
5.15 B USD
1.12 B USD
777.7 M USD
Jan 1, 2007
6 B USD
1.33 B USD
1.02 B USD
Jan 1, 2008
6.72 B USD
1.55 B USD
1.15 B USD
Jan 1, 2009
6.72 B USD
1.66 B USD
1.11 B USD
Jan 1, 2010
7.32 B USD
1.87 B USD
1.27 B USD
Jan 1, 2011
8.31 B USD
1.76 B USD
1.35 B USD
Jan 1, 2012
8.66 B USD
2.24 B USD
1.3 B USD
Jan 1, 2013
9.02 B USD
2.09 B USD
1.01 B USD
Jan 1, 2014
9.68 B USD
2.2 B USD
515 M USD
Jan 1, 2015
9.95 B USD
2.26 B USD
1.44 B USD
Jan 1, 2016
11.33 B USD
2.54 B USD
1.65 B USD
Jan 1, 2017
12.44 B USD
2.75 B USD
1.02 B USD
Jan 1, 2018
13.6 B USD
3.07 B USD
3.55 B USD
Jan 1, 2019
14.88 B USD
3.32 B USD
2.08 B USD
Jan 1, 2020
14.35 B USD
2.9 B USD
1.6 B USD

Stryker Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 27, 2026, 10:05 AM
 
REVENUE (B USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B USD)
NET INCOME (B USD)
NET INCOME GROWTH (%)
DIV. (USD)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
2023202420252026e2027e2028e2029e2030e
20.522.625.1227.5929.932.3834.9338.76
11.1110.2311.169.858.368.37.8810.97
63.964.2664.5758.7854.2550.0946.4341.84
13.114.5216.2216.2216.2216.2216.2216.22
3.172.993.255.846.547.267.669.03
34.22-5.438.4580.0411.9410.945.5917.81
3.053.243.43.528.259.16--
7.776.234.943.53134.3811.03
383.7385.6386.5386.5386.5386.5386.5386.5
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Stryker generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Stryker retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Stryker's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Stryker has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Stryker's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Stryker stock margins

The Stryker margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Stryker. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Stryker.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
68.59 %
21.69 %
15.11 %
Jan 1, 2007
68.92 %
22.12 %
16.96 %
Jan 1, 2008
68.28 %
23.13 %
17.09 %
Jan 1, 2009
67.51 %
24.71 %
16.47 %
Jan 1, 2010
68.77 %
25.61 %
17.4 %
Jan 1, 2011
66.16 %
21.21 %
16.19 %
Jan 1, 2012
67.93 %
25.86 %
14.99 %
Jan 1, 2013
66.72 %
23.13 %
11.15 %
Jan 1, 2014
65.7 %
22.72 %
5.32 %
Jan 1, 2015
66.38 %
22.69 %
14.47 %
Jan 1, 2016
66.39 %
22.44 %
14.54 %
Jan 1, 2017
66.19 %
22.06 %
8.2 %
Jan 1, 2018
65.91 %
22.59 %
26.12 %
Jan 1, 2019
65.4 %
22.27 %
13.99 %
Jan 1, 2020
63.48 %
20.2 %
11.14 %

Stryker Stock Revenue, EBIT, Earnings per Share

The Stryker earnings per share therefore indicates how much revenue Stryker has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
12.5 USD
2.71 USD
1.89 USD
Jan 1, 2007
14.38 USD
3.18 USD
2.44 USD
Jan 1, 2008
16.23 USD
3.75 USD
2.77 USD
Jan 1, 2009
16.85 USD
4.16 USD
2.77 USD
Jan 1, 2010
18.32 USD
4.69 USD
3.19 USD
Jan 1, 2011
21.3 USD
4.52 USD
3.45 USD
Jan 1, 2012
22.6 USD
5.85 USD
3.39 USD
Jan 1, 2013
23.62 USD
5.46 USD
2.63 USD
Jan 1, 2014
25.26 USD
5.74 USD
1.34 USD
Jan 1, 2015
26.1 USD
5.92 USD
3.78 USD
Jan 1, 2016
29.92 USD
6.71 USD
4.35 USD
Jan 1, 2017
32.74 USD
7.22 USD
2.68 USD
Jan 1, 2018
35.76 USD
8.08 USD
9.34 USD
Jan 1, 2019
39.18 USD
8.73 USD
5.48 USD
Jan 1, 2020
37.74 USD
7.62 USD
4.2 USD

Stryker business model & stock analysis

Stryker Corp is a global medical technology company based in Kalamazoo, Michigan, USA. It was founded by Dr. Homer Stryker in 1941 and has since become one of the world's leading providers of medical devices, implants, and medical instruments and accessories. The history of Stryker Corp began over 80 years ago with the invention of the "Gipsbruch", a device developed by Dr. Homer Stryker to better treat broken bones. The Gipsbruch marked the beginning of a new era in orthopedics and led to a comprehensive redefinition of patient care. Over the following decades, Stryker Corp developed further life-saving products and solutions that are used worldwide. Stryker Corp offers a wide range of medical devices, implants, instruments, and accessories to support patient care. The company pursues a strategic growth strategy focused on innovation and acquisitions. This includes the development and marketing of new technologies to enhance patients' quality of life. Stryker Corp is divided into three main divisions: Orthopedics, Medical Technology, and Neurotechnology. The Orthopedics division specializes in the development and manufacturing of implants, instruments, and devices for the treatment of musculoskeletal disorders. The Medical Technology division focuses on the development and manufacturing of devices to support surgical procedures and diagnostics in areas such as endoscopy and emergency medicine. The Neurotechnology division specializes in the development and manufacturing of products for the treatment of neurological disorders such as epilepsy, Parkinson's disease, and hydrocephalus. Some of Stryker Corp's well-known products include the Gipsbruch, which has become a standard device in orthopedics. Other significant products include the hip implant system and the knee implant system, which are widely used and successful in many countries worldwide. Another product of Stryker Corp is the Neptune System, a surgical system that enables the safe and effective use of fluids and gases during surgical procedures. Overall, Stryker Corp is a global medical technology company that originated from the invention of the Gipsbruch and is now one of the leading companies in the manufacturing and development of medical devices and instruments. The company pursues a growth strategy based on innovation and acquisitions and has already produced many successful products. The different divisions, Orthopedics, Medical Technology, and Neurotechnology, each focus on different medical disciplines and offer a wide range of products and solutions to support patient care.

Stryker SWOT Analysis

Strengths

1. Strong market presence: Stryker Corp is a leading global medical technology company known for its innovative products and solutions.

2. Diverse product portfolio: The company offers a wide range of medical devices, orthopedic implants, surgical equipment, and other healthcare products, enabling it to cater to various healthcare needs.

3. Established brand reputation: Stryker Corp has built a strong brand image over the years, known for its quality, reliability, and advanced technology.

4. Strong financial performance: The company has consistently delivered positive financial results, with significant revenue growth and profitability.

Weaknesses

1. Dependence on key markets: Stryker Corp relies heavily on specific geographic regions for its revenue, making it vulnerable to fluctuations in those markets.

2. Vulnerability to regulations: The medical technology industry is subject to stringent regulations and compliance requirements, which may pose challenges for the company's operations.

3. Limited manufacturing capacity: In some product categories, Stryker Corp may face constraints in scaling up production to meet growing demand.

Opportunities

1. Growing global healthcare market: The increasing healthcare needs, particularly in emerging markets, present opportunities for Stryker Corp to expand its customer base and introduce new products.

2. Technological advancements: Stryker Corp can leverage advancements in areas such as robotics, digital health, and artificial intelligence to develop innovative and differentiated products.

3. Expansion through acquisitions: The company can explore strategic acquisitions to enhance its product offerings, enter new markets, or strengthen its existing market presence.

Threats

1. Intense competition: Stryker Corp operates in a highly competitive market, facing competition from both established medical technology companies and new entrants.

2. Economic instability: Fluctuations in global economic conditions can impact healthcare spending, thereby affecting the demand for Stryker Corp's products.

3. Product recalls or liabilities: Any product recalls or legal liabilities related to the company's products could damage its reputation and result in financial losses.

Stryker Segments

Stryker Revenue by Segment (1/5)

  • Max

Neuro Cranial - Interventional Spine
Other MedSurg And Neurotechnology
Other Orthopedics - Enabling Technologies
Details
Date
Neuro Cranial - Interventional Spine
Other MedSurg And Neurotechnology
Other Orthopedics - Enabling Technologies
Jan 1, 2010
0 USD
0 USD
0 USD
Jan 1, 2011
0 USD
0 USD
0 USD
Jan 1, 2012
0 USD
0 USD
0 USD
Jan 1, 2014
0 USD
0 USD
0 USD
Jan 1, 2015
0 USD
0 USD
0 USD
Jan 1, 2016
0 USD
0 USD
0 USD
Jan 1, 2017
0 USD
0 USD
0 USD
Jan 1, 2018
0 USD
0 USD
0 USD
Jan 1, 2019
0 USD
0 USD
0 USD
Jan 1, 2020
0 USD
0 USD
0 USD
Jan 1, 2021
0 USD
0 USD
0 USD
Jan 1, 2022
0 USD
0 USD
0 USD
Jan 1, 2023
0 USD
343 M USD
0 USD
Jan 1, 2024
413 M USD
0 USD
152 M USD
Jan 1, 2025
0 USD
0 USD
0 USD

Stryker Revenue by Segment (2/5)

  • 3 Years

  • 5 Years

  • Max

Trauma and Extremities
Neurovascular
Neurotechnology
Knees
Hips
Medical
Endoscopy
Instruments
Neuro Cranial
Other
Spine
Sustainability
Details
Date
Trauma and Extremities
Neurovascular
Neurotechnology
Knees
Hips
Medical
Endoscopy
Instruments
Neuro Cranial
Other
Spine
Sustainability
Jan 1, 2010
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2011
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2012
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2014
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2015
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2016
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2017
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2018
1.58 B USD
0 USD
1.74 B USD
1.7 B USD
1.34 B USD
2.12 B USD
1.85 B USD
1.82 B USD
0 USD
374 M USD
828 M USD
259 M USD
Jan 1, 2019
588 M USD
0 USD
702 M USD
469 M USD
500 M USD
477 M USD
406 M USD
433 M USD
0 USD
81 M USD
268 M USD
3 M USD
Jan 1, 2020
583 M USD
0 USD
763 M USD
397 M USD
429 M USD
614 M USD
355 M USD
392 M USD
0 USD
77 M USD
283 M USD
3 M USD
Jan 1, 2021
798 M USD
737 M USD
0 USD
497 M USD
520 M USD
600 M USD
471 M USD
474 M USD
226 M USD
124 M USD
336 M USD
0 USD
Jan 1, 2022
772 M USD
754 M USD
0 USD
504 M USD
517 M USD
609 M USD
509 M USD
469 M USD
241 M USD
121 M USD
310 M USD
0 USD
Jan 1, 2023
850 M USD
743 M USD
0 USD
597 M USD
556 M USD
674 M USD
555 M USD
518 M USD
279 M USD
163 M USD
306 M USD
0 USD
Jan 1, 2024
921 M USD
801 M USD
0 USD
659 M USD
645 M USD
661 M USD
597 M USD
567 M USD
375 M USD
208 M USD
218 M USD
0 USD
Jan 1, 2025
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD

Stryker Revenue by Segment (3/5)

  • Max

Trauma and Extremities
Neurovascular
Knees
Hips
Medical
Endoscopy
Instruments
Neuro Cranial
Other
Spine
Details
Date
Trauma and Extremities
Neurovascular
Knees
Hips
Medical
Endoscopy
Instruments
Neuro Cranial
Other
Spine
Jan 1, 2010
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2011
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2012
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2014
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2015
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2016
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2017
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2018
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2019
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2020
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2021
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2022
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2023
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2024
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2025
1.02 B USD
920 M USD
732 M USD
728 M USD
694 M USD
674 M USD
621 M USD
433 M USD
219 M USD
67 M USD

Stryker Revenue by Segment (4/5)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

MedSurg and Neurotechnology
Orthopaedics
Orthopaedics and Spine
MedSurg
Ortho
Neuro and Spine
Neurotechnology and Spine
Details
Date
MedSurg and Neurotechnology
Orthopaedics
Orthopaedics and Spine
MedSurg
United States
Orthopaedic Implants
Ortho
Reconstructive
Neuro and Spine
MedSurg Equipment
Neurotechnology and Spine
Asia Pacific
Other European countries
Europe, Middle East, Africa
Europe Middle East Africa
Other foreign countries
Ireland
Jan 1, 2010
0 USD
0 USD
0 USD
0 USD
4.79 B USD
4.31 B USD
0 USD
0 USD
0 USD
3.01 B USD
0 USD
0 USD
0 USD
0 USD
1.23 B USD
1.3 B USD
0 USD
Jan 1, 2011
0 USD
0 USD
0 USD
3.16 B USD
5.27 B USD
0 USD
0 USD
3.71 B USD
0 USD
0 USD
1.44 B USD
0 USD
1.32 B USD
0 USD
0 USD
1.66 B USD
63 M USD
Jan 1, 2012
0 USD
0 USD
0 USD
3.27 B USD
5.66 B USD
0 USD
0 USD
3.82 B USD
0 USD
0 USD
1.57 B USD
1.34 B USD
0 USD
1.27 B USD
0 USD
397 M USD
0 USD
Jan 1, 2014
0 USD
0 USD
0 USD
3.78 B USD
0 USD
0 USD
4.15 B USD
0 USD
1.74 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2015
0 USD
0 USD
0 USD
3.9 B USD
0 USD
0 USD
4.22 B USD
0 USD
1.83 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2016
0 USD
4.42 B USD
0 USD
4.89 B USD
0 USD
0 USD
0 USD
0 USD
2.01 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2017
0 USD
4.71 B USD
0 USD
5.56 B USD
0 USD
0 USD
0 USD
0 USD
2.17 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2018
0 USD
4.99 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2019
0 USD
5.25 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2020
0 USD
4.96 B USD
0 USD
6.4 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
2.99 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2021
9.54 B USD
0 USD
7.57 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2022
10.61 B USD
0 USD
7.84 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2023
11.84 B USD
0 USD
8.66 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2024
13.52 B USD
9.08 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2025
15.65 B USD
9.47 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD

Stryker Revenue by Segment (5/5)

  • 3 Years

  • 5 Years

  • Max

MedSurg
Neuro and Spine
Neurotechnology and Spine
Details
Date
MedSurg
Neuro and Spine
Neurotechnology and Spine
Jan 1, 2010
0 USD
0 USD
0 USD
Jan 1, 2011
0 USD
0 USD
0 USD
Jan 1, 2012
0 USD
0 USD
0 USD
Jan 1, 2014
0 USD
0 USD
0 USD
Jan 1, 2015
0 USD
0 USD
0 USD
Jan 1, 2016
0 USD
0 USD
0 USD
Jan 1, 2017
0 USD
0 USD
0 USD
Jan 1, 2018
6.05 B USD
0 USD
2.57 B USD
Jan 1, 2019
6.57 B USD
3.06 B USD
0 USD
Jan 1, 2020
0 USD
0 USD
0 USD
Jan 1, 2021
0 USD
0 USD
0 USD
Jan 1, 2022
0 USD
0 USD
0 USD
Jan 1, 2023
0 USD
0 USD
0 USD
Jan 1, 2024
0 USD
0 USD
0 USD
Jan 1, 2025
0 USD
0 USD
0 USD

Stryker Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

United States
International
Europe, Middle East, Africa
Asia Pacific
Europe, Middle East, and Africa
Other foreign countries
Details
Date
United States
International
Europe, Middle East, Africa
Asia Pacific
Europe, Middle East, and Africa
Other foreign countries
Jan 1, 2014
6.56 B USD
0 USD
0 USD
1.37 B USD
1.37 B USD
378 M USD
Jan 1, 2015
7.12 B USD
0 USD
0 USD
1.25 B USD
1.27 B USD
312 M USD
Jan 1, 2016
8.25 B USD
0 USD
1.44 B USD
1.31 B USD
0 USD
322 M USD
Jan 1, 2017
9.06 B USD
0 USD
1.57 B USD
1.41 B USD
0 USD
405 M USD
Jan 1, 2018
3.38 B USD
1.61 B USD
1.79 B USD
1.53 B USD
0 USD
428 M USD
Jan 1, 2019
10.96 B USD
3.93 B USD
1.89 B USD
1.62 B USD
0 USD
422 M USD
Jan 1, 2020
10.46 B USD
3.9 B USD
1.82 B USD
1.63 B USD
0 USD
448 M USD
Jan 1, 2021
12.32 B USD
4.79 B USD
2.3 B USD
1.97 B USD
0 USD
515 M USD
Jan 1, 2022
13.64 B USD
4.81 B USD
2.35 B USD
1.89 B USD
0 USD
578 M USD
Jan 1, 2023
15.26 B USD
5.24 B USD
2.62 B USD
1.95 B USD
0 USD
677 M USD
Jan 1, 2024
16.94 B USD
5.65 B USD
2.9 B USD
2.02 B USD
0 USD
735 M USD
Jan 1, 2025
19.01 B USD
6.11 B USD
3.18 B USD
2.16 B USD
0 USD
765 M USD

Stryker Eulerpool Fair Value

Stryker historical P/E ratio, EBIT multiple, and P/S ratio

Stryker annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Stryker shares outstanding

The number of shares was Stryker in 2025 — This indicates how many shares 386.5 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
411.8 M base_Shares
Jan 1, 2007
417.2 M base_Shares
Jan 1, 2008
414 M base_Shares
Jan 1, 2009
399 M base_Shares
Jan 1, 2010
399.5 M base_Shares
Jan 1, 2011
390 M base_Shares
Jan 1, 2012
383 M base_Shares
Jan 1, 2013
382 M base_Shares
Jan 1, 2014
383 M base_Shares
Jan 1, 2015
381 M base_Shares
Jan 1, 2016
378.5 M base_Shares
Jan 1, 2017
380.1 M base_Shares
Jan 1, 2018
380.3 M base_Shares
Jan 1, 2019
379.9 M base_Shares
Jan 1, 2020
380.3 M base_Shares

Stryker Dividend History

30 years of dividend payments · 10 consecutive increases

YearAnnual DividendYoY ChangePayments
20260.88USDYTD
Mar 31, 20260.88USD 0.0%1/1
20253.4USD 4.9%
Mar 31, 20250.84USD 0.0%1/4
Jun 30, 20250.84USD 0.0%2/4
Sep 30, 20250.84USD 0.0%3/4
Dec 31, 20250.88USD 4.8%4/4
20243.24USD 6.2%
20233.05USD 7.6%
20222.84USD 9.7%
20212.59USD 9.8%
20202.36USD 10.3%
20192.14USD 10.6%
20181.93USD 10.6%
20171.74USD 11.5%

Stryker dividend history and estimates

In 2025, Stryker paid a dividend amounting to 3.4 USD. Dividend means that Stryker distributes a portion of its profits to its owners.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2006
0.22 USD
0 USD
Jan 1, 2007
0.33 USD
0 USD
Jan 1, 2008
0.4 USD
0 USD
Invalid Date
0.25 USD
0.25 USD
Jan 1, 2010
0.63 USD
0 USD
Jan 1, 2011
0.75 USD
0 USD
Jan 1, 2012
0.9 USD
0 USD
Jan 1, 2013
1.63 USD
0 USD
Jan 1, 2014
1.87 USD
0 USD
Jan 1, 2015
1.42 USD
0 USD
Jan 1, 2016
1.57 USD
0 USD
Jan 1, 2017
1.74 USD
0 USD
Jan 1, 2018
1.93 USD
0 USD
Jan 1, 2019
2.14 USD
0 USD
Jan 1, 2020
2.36 USD
0 USD

Stryker dividend payout ratio

In 2025, Stryker had a payout ratio of 48.37%. The payout ratio indicates the percentage of the company's profits that Stryker distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
11.76 %
Jan 1, 2007
13.58 %
Jan 1, 2008
14.39 %
Jan 1, 2009
9.03 %
Jan 1, 2010
19.75 %
Jan 1, 2011
21.81 %
Jan 1, 2012
26.62 %
Jan 1, 2013
61.98 %
Jan 1, 2014
138.52 %
Jan 1, 2015
37.43 %
Jan 1, 2016
35.98 %
Jan 1, 2017
65.11 %
Jan 1, 2018
20.66 %
Jan 1, 2019
38.96 %
Jan 1, 2020
56.07 %
Price targets and forecasts for Stryker are not yet available.

Stryker Earnings Estimates

Stryker Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
4/30/20263.01USD6.4 BUSD2026 Q1
1/29/20264.44USD7.19 BUSD2025 Q4
4/29/20242.56USD5.17 BUSD2024 Q1
1/29/20243.3USD5.65 BUSD2023 Q4
7/24/20232.4USD4.78 BUSD2023 Q2
4/26/20232.16USD4.54 BUSD2023 Q1
1/25/20232.86USD5.03 BUSD2022 Q4
10/31/20222.25USD4.52 BUSD2022 Q3
7/26/20222.3USD4.6 BUSD2022 Q2
4/28/20221.97USD4.25 BUSD2022 Q1
...

EESG©

Eulerpool ESG Scorecard© for the Stryker stock

70/100
53
Environment
82
Social
75
Governance
E

Environment

20
Scope 1 - Direct Emissions57,383
Scope 2 - Indirect emissions from purchased energy117,059
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions174,442
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees38.5
Percentage of women in management
Percentage of Asian employees7.7
Share of Asian management11.8
Percentage of Hispanic/Latino employees10.9
Hispano/Latino Management share5.6
Percentage of Black employees6.1
Black Management Share2.7
Percentage of white employees72
White Management Share77.8
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Stryker shareholder structure

% Name
8.73091%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.1892%
Brown (John W)
Brown (John W)
4.35649%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.28569%
Greenleaf Trust
Greenleaf Trust
3.94681%
State Street Investment Management (US)
State Street Investment Management (US)
2.48528%
T. Rowe Price Associates, Inc.
T. Rowe Price Associates, Inc.
2.07113%
JP Morgan Asset Management
JP Morgan Asset Management
1.9497%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
1.68002%
Wellington Management Company, LLP
Wellington Management Company, LLP
1.66736%
AllianceBernstein L.P.
AllianceBernstein L.P.
...

Stryker Executives and Management Board

KL

Mr. Kevin Lobo

(60)

Chairman of the Board, President, Chief Executive Officer · since 2011

Compensation21.98 M USD
SS

Mr. Spencer Stiles

(49)

President, Chief Operating Officer

Compensation6.76 M USD
JP

Mr. J. Andrew Pierce

(51)

Group President - MedSurg and Neurotechnology

Compensation6.76 M USD
VM

Mr. Viju Menon

(57)

Group President - Global Quality and Operations

Compensation4.59 M USD
RF

Mr. Robert Fletcher

(54)

Vice President, Chief Legal Officer

Compensation2.24 M USD

Stryker Supply Chain

Frequently asked questions about Stryker

The business model of Stryker Corp focuses on providing innovative medical technologies and solutions worldwide. As a leading medical technology company, Stryker Corp specializes in products and services across various segments, including orthopedics, medical and surgical, neurotechnology, and spine. With a strong emphasis on research and development, Stryker Corp strives to deliver advanced and effective healthcare solutions to improve patient outcomes. The company's commitment to innovation, quality, and customer satisfaction has made it a trusted name in the medical industry. Stryker Corp's business model revolves around leveraging its expertise and cutting-edge technologies to meet the evolving needs of healthcare professionals and enhance the lives of patients.

All fundamentals and in-depth analysis of Stryker

Our stock analysis for Stryker Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stryker Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.